A Clinical study of garlicin in treating acute cerebral infarction

Objective: To evaluate the effect of garlicin in treating acute cerebral infarction.Methods: One hundred and one patients of acute cerebral infarction diagnosed by CT were treated with garlicin (garlicin group) and compared with another group of 53 patients treated with ligustrazine (control group). The neurologic deficiency score and neurologic function score were used for evaluation of effect.Results: The effective rates of garlicin and ligustrazine were 89. 36% and 84. 85% respectively. The improvement scores of neurologic function were 18.46±10.69 and 11.94 ± 6.79 respectively. The difference between the two groups was significant. Before treatment the serum level of MDA in the garlicin group was 6.015 ±1.26 nmol/ml, and it decreased to 4. 87 ± 1.16 nmol/ml after treatment, the change being more significant than that of the control group (from 6.02 ±0.73 nmol/ml to 6.47 ±1.04 nmol/ml). The rheological parameters and cerebral blood flow were also improved after garlicin treatment.Conclusion: Garlicin could increase the perfusion flow of brain, improve the microcirculation, and scavenge free radicals so as to relieve the ischemia and reperfusion injury of the brain.